Background Curative resection is the treatment of choice for gastric cancer, but it is unclear
whether this operation should include an extended (D2) lymph-node dissection, as …

Purpose The extent of lymph node dissection appropriate for gastric cancer is still under
debate. We have conducted a randomized trial to compare the results of a limited (D1) and …

Background In the United States of America, the five-year survival rate among patients
surviving curative resection for gastric carcinoma will range between 20 and 25 percent. In …

Background The survival benefit and morbidity after nodal dissection for gastric cancer
remains controversial. We aimed to do a single-institution randomised trial to compare D1 …

Background: The use of extended (D2) lymph node dissection in gastric cancer achieves
better locoregional tumor control than limited (D1) lymphadenectomy, but its influence on …

Background: Although curative resection is the treatment of choice for gastric cancer,
controversy exists about the adequate extent of lymph node dissection when resection is …

Background Extragastric lymphadenectomy (D2 node dissection) is strongly supported by
Japanese data to have survival benefit. Randomized trial data are either inconclusive or …

The results for 162 patients who underwent curative gastrectomy for gastric cancer from
January 1988 to June 1994 were analysed statistically with special reference to the effect of …

The purpose of this study was to determine whether extended lymph node (D2) dissection is
associated with a survival benefit for patients with histologically node-negative gastric …

BACKGROUND: A multicenter, randomized, clinical trial was initiated to evaluate the
possible benefits of extended D2 (D2+) lymphadenectomy after potentially curative resection …